Levofloxacina Kabi (Levofloxacin Hemihydrate)

Levofloxacina Kabi is a fluoroquinolone antibacterial indicated for several serious infections caused by susceptible bacteria.

• Community‑acquired respiratory tract infections: achieves clinical cure and microbiological eradication of pathogens such as Streptococcus pneumoniae.
• Complicated urinary tract infections: resolves infection and prevents recurrence in patients with renal involvement.
• Skin and soft tissue infections: provides rapid bacterial clearance in cellulitis and wound infections.
• Intra‑abdominal infections: treats polymicrobial infections following surgery or perforation.
• Severe bacterial infections caused by susceptible organisms: offers broad‑spectrum coverage for life‑threatening sepsis.

• Levofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By stabilizing the enzyme‑DNA complex, it prevents DNA strand separation, halting bacterial DNA synthesis and transcription, which leads to bacterial cell death. The drug exhibits concentration‑dependent bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

Levofloxacina Kabi may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Headache: transient and often resolves without intervention.
• Dizziness: occasional sense of light‑headedness.
• Rash: mild erythematous skin eruption.

Serious or Rare Side Effects

• Tendon rupture: especially Achilles tendon, may occur without warning.
• QT interval prolongation: can precipitate cardiac arrhythmias.
• Clostridioides difficile infection: severe colitis requiring medical management.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Hepatic dysfunction: elevated transaminases or jaundice.
• Seizures: particularly in patients with CNS disorders or concomitant pro‑convulsant drugs.

Levofloxacina Kabi requires careful assessment of patient‑specific factors before use.

• Renal function: adjust therapy in patients with impaired clearance to avoid accumulation.
• Hepatic impairment: monitor liver enzymes in patients with existing liver disease.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Tendon health: counsel patients to report tendon pain, swelling, or inflammation promptly.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight, and retain in the original sealed container.

Levofloxacina Kabi can interact with several drug classes, influencing safety or efficacy.

Major Interactions (Avoid)

• Other fluoroquinolones: additive risk of tendon toxicity and QT prolongation.
• Antacids or supplements containing magnesium, aluminum, calcium, or iron: markedly reduce levofloxacin absorption.
• Drugs that prolong QT interval (e.g., macrolides, antiarrhythmics): increase risk of serious cardiac arrhythmias.
• Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.
• NSAIDs: heightened risk of central nervous system stimulation and seizures.

Moderate Interactions (Monitor Closely)

• CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine): may increase levofloxacin plasma levels.
• Corticosteroids: combined use raises tendon rupture risk.
• Oral hypoglycemic agents or insulin: may cause hypoglycemia; monitor blood glucose.
• Theophylline: levofloxacin can raise theophylline concentrations, risking toxicity.